Demethylating Agent Restores RIP3 Expression in Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies face challenges in triple-negative breast cancer patients due to low expression of RIP3, leading to resistance to anticancer drugs, as RIP3 plays a crucial role in enhancing drug sensitivity and promoting cell death.
Innovation Solution
A pharmaceutical composition comprising a demethylating agent to induce RIP3 expression, combined with an anticancer drug, to enhance sensitivity by promoting demethylation of methylated RIP3 protein, along with methods for screening and monitoring RIP3 expression to optimize treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anticancer drugs are administered to patients with low RIP3 expression, then cancer cell death should increase, but the drugs become ineffective due to resistance
Solution Approach 1:
The patent applies preliminary action by administering a demethylating agent before anticancer drugs to restore RIP3 expression. The demethylating agent pretreats the cancer cells by removing methyl groups from the RIP3 gene promoter region, thereby reactivating RIP3 expression prior to drug administration, which makes the subsequent anticancer therapy effective
Solution Approach 2:
The patent changes the epigenetic parameter (methylation status) of the RIP3 gene to alter its expression level. By using demethylating agents to modify the methylation state of the RIP3 promoter, the gene expression is restored from a suppressed state to an active state, thereby reversing drug resistance
2Reliability
If demethylating agents are used to restore RIP3 expression, then drug sensitivity increases, but the treatment complexity increases
Solution Approach 1:
The patent merges two therapeutic agents (demethylating agent and anticancer drug) into a single treatment regimen. The demethylating agent and anticancer drug are administered in sequence to achieve both RIP3 expression restoration and cancer cell killing in one integrated therapy protocol
Solution Approach 2:
The demethylating agent serves as an intermediary that mediates between the anticancer drug and the resistant cancer cells. It first modifies the epigenetic state of the cells to make them susceptible to the subsequent anticancer drug treatment, acting as a bridge that overcomes the resistance barrier
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly increases anticancer drug sensitivity by restoring RIP3 expression, sensitizing cancer cells to chemotherapy, and improving treatment outcomes in patients with low RIP3 expression, as demonstrated by increased cell death and reduced tumor volume in preclinical models.
Implementation Method 1
a demethylating agent enhances anticancer drug sensitivity by inducing demethylation of methylated receptor-interacting protein kinase-3 (RIP3) protein
Data Source
AI summary
The present invention relates to a pharmaceutical composition for an anticancer adjuvant comprising a receptor-interacting protein kinase-3 (RIP3) protein expression promotor or activator as an active ingredient. In addition, the present invention provides a method of promoting cancer cell apoptosis, characterized by co-administering an anticancer agent and a RIP3 protein expression promotor or activator to cancer cells. Also, the present invention relates to a method for screening an anticancer adjuvant which promotes RIP3 expression and enhances sensitivity of an anticancer agent, and a method for monitoring sensitivity of an anticancer agent depending on the RIP3 expression. Accordingly, in the case of a patient lacking the expression of RIP3, it is expected to be an effective treatment strategy to pre-treat a demethylating agent to induce the expression of RIP3 and then to use a conventional chemotherapeutic agent. In addition, in chemotherapy, it is anticipated that the present invention may be an effective strategy in screening an anticancer adjuvant which monitors and enhances sensitivity of an anticancer agent.